A revolutionary HIV prevention drug should be available to patients in low and middle income countries by 2027 at an affordable price.
The drug, whose technical name is Lenacapavir, reduces the risk of infection by more than 99.9% and it is the first long acting treatment that can prevent a person catching HIV. Developer Gilead Sciences normally charges more than 28,000 dollars for a year’s supply. Now charities including the Gates Foundation say they will help two Indian drugmakers develop generic versions of the medicine. And a year’s dose will cost USD 40 per patient.
Chapters:
0:00 The AIDS drug
0:43 Angei Achrekar, UNAIDS Deputy Director
For more news go to: http://www.dw.com/en/
Follow DW on social media:
►Instagram: https://www.instagram.com/dwnews
►TikTok: https://www.tiktok.com/@dwnews
►Facebook: https://www.facebook.com/deutschewellenews/
►Twitter: https://twitter.com/dwnews
Für Videos in deutscher Sprache besuchen Sie: https://www.youtube.com/dwdeutsch
Subscribe: https://www.youtube.com/user/deutschewelleenglish?sub_confirmation=1
#aids #income #hiv
Author: DW News
Go to Source
News post in September 25, 2025, 12:05 am.
Visit Our Sponsor’s:
News Post In – News
